Colworth Park
  • MIP Diagnostics creates new Covid sensor

    Colworth based MIP Diagnostics Ltd has today announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices. nanoMIPs are nanoscale Molecularly Imprinted Polymers, commonly known as synthetic antibodies. They are manufactured around a template molecule in a […]

    Read More

  • New Antibiotic Resistance Test Developed by AGPlus Diagnostics

    With the support of UKRI and the UK Innovation & Science Seed Fund, Colworth Park based AgPlus Diagnostics have developed a 15-minute test that can distinguish between viral and bacterial infections.  This ability for point of care testing will help doctors to prescribe antibiotics only to the patients that need them and not unnecessarily to patients with […]

    Read More

  • AgPlus Developing two assays to support the COVID-19 diagnostic effort.

    Colworth Park based AgPlus has been working on an antigen assay and antibody assay and have successfully secured grants from Innovate UK and DASA to support the work. Recognising the need to respond quickly they have utilised thier proven lab-based electrochemistry technology, originally developed at the National Physical Laboratory and adapted this as a desk […]

    Read More

  • MIP Diagnostics secures £5.1m in funding to expand commercial operations and production

    Colworth Park based nanotechnology business, MIP Diagnostics, has completed a £5.1m funding round to accelerate its global expansion. The co-investment has come from Mercia Asset Management, a founding investor and the largest shareholder in the company, and was led by Downing Ventures (£1.4m), BGF (£2m) and Calculus Capital. MIP Diagnostics has developed a proprietary process […]

    Read More

  • Concepta inks global licence agreement with Abingdon Health

    Colworth Park cased Concepta Diagnostics has signed an exclusive global licence agreement with Abingdon Health for the use of its App Dx IP for human pregnancy and fertility. The UK-personalised healthcare company said the deal will allow its customers to access rapid test results, further information and remain connected with supporting services at home. A […]

    Read More

  • Stream Bio collaborates with MIP Diagnostics Ltd. on a rapid diagnostic and mass screening test for COVID-19

    Stream Bio, a company that develops and manufactures a range of transformative bioimaging molecular probes, is delighted to announce a new joint venture with Colworth based MIP Diagnostics Ltd., a world leader in molecular imprinting for diagnostic and other applications. The collaborative project will focus on the development of a COVID-19 (or SARS-Cov-2) antigen reagent […]

    Read More

  • Veravas and MIP Diagnostics Announce International Agreement for Improved Diagnostics

    Veravas, Inc., an emerging diagnostic company focusing on sample preparation products and new diagnostic tests and MIP Diagnostics Ltd., the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, announced today that they have entered into a mutually beneficial agreement for the development, license, and supply of a novel MIP specific for Veravas’ proprietary […]

    Read More

  • Harrison Street and Trinity acquire portfolio of five UK life sciences and innovation properties

    Harrison Street, an alternative real asset investment firms dedicated to the Education, Healthcare and Storage sectors, and Trinity Investment Management (Trinity), an operator, developer and manager of UK real estate focused in the life sciences and innovation space, are to acquire a portfolio of five life sciences and innovation properties across the UK. As part […]

    Read More

  • MIP Diagnostics Ltd. Signs Significant Commercial Agreement for Novel Security Applications

    MIP Diagnostics Ltd, the Molecularly Imprinted Polymers (MIPs) specialist based at Colworth Park, has today announced a collaborative agreement with commercial partners for the co-development and license of a novel MIP-based system with specific applications in the security field. The long-term benefits of the deal could have ground breaking implications in the target applications and […]

    Read More

  • Seasoned medical device company boss, Mark Harwood joins Camstent as CEO

    Camstent Ltd., the Colworth Park based company applying proprietary bacteria-phobic polymer coatings to medical devices, announces the appointment of Mark Harwood as CEO. Mark is a respected figure with an exceptional track record in the medical device sector. Mark is returning to the UK from Malaysia where he spent two and a half years undertaking […]

    Read More